Update shared on 08 Dec 2025
Analysts have modestly adjusted their price target on Canopy Growth, citing largely unchanged assumptions for fair value at approximately 3.30 dollars, a stable discount rate near 6.12 percent, and essentially flat outlooks for revenue growth, profit margins, and future valuation multiples.
What's in the News
- Launched Claybourne Gassers All in One vapes featuring high potency liquid diamonds and anti clog, anti burn technology, along with new Claybourne Frosted Flyers infused pre roll variety packs in select Canadian regions and online medical channels (Key Developments)
- Expanded the Spectrum Therapeutics portfolio in Australia with new CBD, THC, and balanced softgel capsules, deepening the company’s presence in the maturing Australian medical cannabis market (Key Developments)
- Shareholders approved amendments to the company’s articles to allow a potential consolidation of common and exchangeable shares, giving the board discretionary authority to implement a reverse split within 12 months (Key Developments)
- Transitioned the DOJA facility in Kelowna, British Columbia, into an exclusive medical cultivation site under a micro cultivation license, focused on small batch craft cannabis for Spectrum Therapeutics patients, including veterans (Key Developments)
- Appointed Tom Stewart as permanent Chief Financial Officer, formalizing his role after serving as interim CFO and leading efforts to stabilize the balance sheet, cut expenses, and improve liquidity (Key Developments)
Valuation Changes
- Fair Value: Unchanged at approximately CA$3.30 per share, indicating no material revision to intrinsic value estimates.
- Discount Rate: Maintained at 6.118 percent, a negligible level with no meaningful impact on valuation.
- Revenue Growth: Held steady at around 5.40 percent, reflecting an essentially unchanged outlook for top line expansion.
- Net Profit Margin: Remained effectively flat at roughly 3.08 percent, signaling no significant adjustment to long term profitability assumptions.
- Future P/E: Stable at about 164.25x, suggesting analysts see no meaningful change in the long term earnings multiple applied to the stock.
Have other thoughts on Canopy Growth?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.